Protocol Ledger

NCT04552899 · Phase III · TERMINATED

A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

Interventional Phase III clinical trial protocol NCT04552899 sponsored by Roche / Genentech in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-19 Enrollment: 665 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04552899
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)665 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04552899
Protocol FieldVerified Registry Value
NCT IdentifierNCT04552899
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment665 participants (ACTUAL)
Registered Start Date2021-03-19
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI